The effort, which relied on Oxford BioDynamics' EpiSwitch platform, resulted in an assay that researchers believe could be developed into a test to guide therapy selection for patients.
The partners will perform blood-based tests on Oxford's Episwitch platform to monitor epigenetic changes of athletes with concussions.
The British company has announced the results of two studies showcasing the ability of its EpiSwitch platform to diagnose and stage breast cancer and ALS patients.
Nova Satra said it will use the EpiSwitch technology to develop and commercialize non-invasive breast cancer testing across 13 territories in Asia.
Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.
Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.
In Science this week: research regulation and reporting requirement reform, and more.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.